HMNC Brain Health Begins Phase 2 Study for Personalized Treatment of Stress-Axis Related Major ...

MUNICH, Germany, June 20, 2023 (GLOBE NEWSWIRE) -- HMNC Brain Health (‘‘HMNC’’ or the ‘‘Company’’), a global clinical-stage biopharmaceutical company pioneering the development of personalized therapies in psychiatry, announced today

Related Keywords

Germany ,Munich ,Bayern ,Hans Eriksson ,Sophia Bashford ,Anne Donohoe ,Maximilian Doebler ,Holding Gmb ,Brain Health ,Major Depressive Disorder ,Chief Business Officer ,Chief Medical Officer ,Treatment Resistant Depression ,